Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label brexpiprazole adjunctive treatment in elderly MDD patients
2014-003547-35Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brexpiprazole in major depressive disorder (MDD), sponsored by Lundbeck. Primary endpoint: Long-term safety and tolerability of brexpiprazole as adjunctive treatment. Started Feb 2015; status: completed.
02
Drugs
brexpiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2014-003547-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003547-35.